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 1 
Summary  
 
Background 
In December 2002, Scotland’s Lord Advocate reviewed the Guidelines that govern 
the number of needles and syringes (n/s) dispensed at any one visit to a needle 
exchange.  The new Guidelines increased the number that could be distributed to a 
maximum of 20 sets (previously 5 sets) on the first visit; a maximum 60 sets 
(previously 15 sets) on subsequent visits; and an exceptional upper limit of 120 sets 
(previously 30 sets) for holiday periods when facilities are closed or are difficult to 
access. These exchanges are subject to the return of used equipment for safe 
disposal.  This study set out to evaluate the effects of this change on IDUs’ risk 
behaviours. 
Aim 
The aim of the evaluation was to determine if increasing the supply of sterile needles 
and syringes to injectors reduces the frequency of needle and syringe sharing.  
The main objectives of the study were to ascertain if the lifting of the Lord 
Advocate’s restriction on the number of needles and syringes distributed to injectors: 
1. reduces the frequency of needle and syringe sharing among injectors; 
2. causes any other behavioural changes among injectors, either beneficial or 
detrimental, e.g. frequency of visits to needle exchange 
The evaluation also sought to determine the views of needle exchange and pharmacy 
workers on the increase in supply of needles and syringes.  
Methodology 
Evaluating the impact on risk behaviours 
The study originally set out to evaluate the effects of the new Guidelines by 
comparing the risk behaviours among recent initiates to injecting (i.e had injected for 
six years or less) among Glasgow IDUs in 2004 with the behaviours of recent 
initiates to injecting who had been interviewed in 2001-2002.  Recruitment of IDUs 
commenced a year after the introduction of the new Guidelines.  However it very 
quickly became apparent that most IDUs were unaware that they could now obtain 
an increased number of sterile n/s per visit.  It was clear that the aim of determining 
if the increase in supply had reduced risk behaviours could not be achieved.  
An awareness campaign was incorporated into a new study design.  This campaign, 
consisting of cards and posters displayed in, and distributed through, pharmacies, 
needle exchanges and drug treatment centres, aimed to inform IDUs that they could 
now collect more n/s and also included harm reduction advice.  
The new study design changed to include all current injectors i.e. those who had 
injected at least once in the four weeks prior to interview.  This allowed the 
recruitment of a more representative sample of injectors than in the original 
proposed method.  Injectors within the sample who had begun injecting within the 
previous six years would still be compared to the respondents in 2001-2002 study to 
determine if there had been any change in behaviours over this longer period. 
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Between February and May 2004, prior to the introduction of the awareness 
campaign, 296 IDUs, all of whom had injected in the previous month, were recruited 
to the study from a variety of venues including street sites, pharmacies, needle 
exchanges and drug treatment centres.  They were interviewed with a structured 
questionnaire that contained questions on their drug use habits and risk behaviours.  
The results of this phase of the study formed a baseline against which any changes 
in behaviour following the implementation of the awareness campaign could be 
measured. 
Six weeks after the introduction of the awareness campaign, recruiting for the post 
awareness sample began and 299 IDUs were interviewed over a three-month period. 
 
Evaluation of the views of needle exchange and pharmacy workers 
Two members of staff from each pharmacy and needle exchange from which IDUs 
were recruited were interviewed.  Staff members were asked a series of structured, 
open-ended questions about their views on the increase in supply of needles and 
syringes.  These included their perceptions of any impact the Lord Advocates 
guidance had on their service including frequency of attendance by drug users and 
any impact on return of used n/s. 
 
Results 
The impact on risk behaviours 
The characteristics of the participants in the pre and post campaign phases were 
comparable with respect to proportion of males (86% and 83% respectively); age at 
interview (mean 32 years in both); age at first injection (mean 21 years in both); 
length of injecting career (mean 11 years in both); recruitment setting (79% and 
86% recruited in street respectively); type of residence in the six months prior to 
interview (hostel accommodation 37% and 36% respectively); and having ever been 
in treatment for drug use (93% and 88% respectively).  Heroin was the most 
common drug injected (by 93%) in both samples. 
A significantly higher proportion of participants from the post awareness campaign 
phase (54%) injected drugs twice daily or more compared to those recruited pre-
campaign (44%). 
There were no significant differences in injecting risk behaviours in the four weeks 
prior to interview.   Almost 80% in both sweeps reported never having injected with 
a n/s previously used by someone else.  
There was no significant difference in the number of n/s obtained in an average week 
from a pharmacy or needle exchange between the pre and post awareness surveys.  
Pre-awareness respondents obtained an average of 26 n/s (median=20) and post 
awareness IDUs received an average of 27 n/s (median=30) per visit. 
There was a significant decrease in the number of respondents obtaining sterile n/s 
from non-exchange sources (i.e. friends, other drug users, on street, sexual partner, 
family, theft and drug dealers) in the post awareness phase.   
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The maximum number of needles and syringes that IDUs believed could be obtained 
per visit from a pharmacy or needle exchange increased significantly from a median 
of 20 n/s to a median of 25 n/s, an increase of 25%, between the pre and post 
awareness surveys. Few injectors, however, knew that the limit had been changed in 
either the pre or post surveys (20% in both).  
The majority of IDUs in both surveys did not want to obtain as many as 60 n/s per 
visit and they were, moreover, generally satisfied with the number they were 
currently receiving (a mean of 19 and 21 (median 15 and 15), pre and post 
awareness campaign respectively).  In both samples, the main reason for not 
wishing to obtain a greater number was that this was enough for their injecting 
needs (206/359, 57%).  Despite this claim, half of these respondents (181/359, 
50%) stated that, on average, they injected with the same needle more than once.  
Among IDUs who did wish to receive more n/s than they were currently receiving 
(236/595, 40%) the most common reason was to cut down the number of visits to 
the needle exchange (74/236, 31%).  
In the 2004 survey, 170 IDUs had begun injecting in the previous six years and their 
behaviours were compared with those of 385 IDUs with the same length of injecting 
careers who had been interviewed in 2001-2002. 
Injecting of cocaine (on its own) had increased with just over half of recent initiates 
reporting use of cocaine in the previous months in 2004 compared with just under 
two-fifths of IDUs in 2001-2002.  With the increase of cocaine use it might have 
been expected that the frequency of injecting would also increase, however there 
was a significant decrease in the frequency of injecting in the previous six months in 
the 2004 sample compared with the 2001-2002 survey. 
Moreover, those interviewed in 2004 were significantly less likely to inject with a n/s 
previously used by someone else; just over half of the 2001-2002 sample had 
injected in the previous six months with a n/s previously used by someone else 
compared with a quarter in 2004.   
Views of needle exchange staff 
Forty staff were interviewed about their views on the new Guidelines.  This included 
19 pharmacy assistants, 14 pharmacists, 2 nurses and 5 team workers. 
The majority of staff (37/40) knew about the new Guidelines and nearly two-thirds 
(25/40) could correctly cite the maximum number of n/s that could be given out per 
visit.   
Almost all (36/40) said that they had informed clients of this change.  However, it 
appeared that, apart from displaying information about the new Guidelines, some 
staff directly told IDUs of the change only if asked.  Other staff were more pro-active 
and explained the change to clients and encouraged them to take more n/s. 
Just over a third of staff approved of the new Guidelines, with one third disapproving 
and the remainder having mixed views.  Furthermore, whilst just under two-thirds 
said that the number of n/s that they dispensed depended on the number of returns 
they received, some respondents said that they decided what to dispense according 
to how well they knew the client 
There were mixed views on the impact that the Guidelines had on exchanges. A third 
felt that the change in guidance had no impact on the pharmacy/exchange while 
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nearly a quarter believed that the frequency of visits by individuals had reduced.  
The remainder cited a variety of changes including an increase in numbers of clients 
(7/40), a decrease in clients (6/40) and an increase in frequency of visits (3/40). 
Conclusion 
More than a year after the introduction of the Lord Advocate’s new Guidelines, very 
few IDUs in Glasgow were aware of the increase in the maximum number of n/s that 
could be obtained per needle exchange visit; even a specially designed, targeted 
campaign failed to raise awareness.   
After the introduction of the new Guidelines, needle exchanges and pharmacies 
displayed information and informed IDUs.  The results of the staff survey, however, 
indicated that some staff did not actively promote the increase to services users.  
Moreover, only one-third of staff approved of the new guidelines and some used their 
own judgement in deciding how many n/s should be given out.   
It may be that the reluctance to implement, or disapproval of, the Guidelines among 
some staff was one reason for the low level of awareness among IDUs.  Needle 
exchange and pharmacy staff need, therefore, to be made more aware of the 
necessity to actively provide oral advice and information to their clients.   
The attitude of some staff, however, does not explain why the targeted awareness 
campaign also failed to inform the majority of IDUs.  Posters and cards were 
distributed to all exchange outlets and the cards were inserted in all n/s packs.  Yet 
this strategy, too, failed to increase knowledge among IDUs. 
One of the study findings indicated that IDUs did not, generally, wish to have any 
more n/s than they were currently receiving.  The message contained in the 
awareness campaign (or imparted by pharmacists) that more n/s were available was 
therefore meaningless to them.  The main reason for not wanting more n/s was that 
the current level was sufficient for their needs.  However it was noted that half of 
these IDUs were re-using their own n/s; yet the awareness campaign cards alerted 
IDUs to the risks involved in this.  
Due to time constraints, the time period for the awareness campaign was six weeks.  
After this period, recruitment for the post awareness group began.  Cards and 
posters were distributed to agencies throughout the city and were placed inside the 
packs of n/s that are distributed through the pharmacy exchanges.  The cards placed 
within the packs, however, would not have reached some injectors until towards the 
end of the recruitment period.  It may be that if the campaign had run for a longer 
period it would have had more impact.  
There is some evidence, however, that leaflets are not successful in communicating 
messages to IDUs (Wright et al).  Some IDUs may, for example, have literacy 
problems that render written material ineffective.  There is perhaps a need to 
evaluate the readability of written harm reduction materials and to design and 
evaluate new ways of delivering harm reduction messages to IDUs. 
Nevertheless, there have been some positive changes in behaviours among IDUs in 
Glasgow since the introduction of the awareness campaign and since 2001.   
The maximum number of n/s that IDUs believed could be obtained per visit from a 
pharmacy or needle exchange increased significantly.  Respondents were also less 
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likely to obtain sterile n/s from non-legitimate sources in the post awareness phase.  
Whilst frequency of injecting had increased, there was no increase in sharing 
behaviour.  A comparison between recent initiates to injecting in 2001-2002 and 
2004 found a decrease in both frequency of injecting and sharing in 2004. 
These changes cannot definitely be proved to arise directly from the increased 
availability of n/s; other factors may have influenced behaviour between 2001-2002 
and 2004. Nevertheless, the association between the introduction of the new 
Guidelines and behaviour changes suggests that the former may be having a positive  
impact. It would seem prudent to continue with the current policy on n/s distribution.  
However, the findings from this study suggest that further work needs to be done 
among needle exchange staff to inform IDUs of their entitlement to a greater 
number of n/s and to encourage them to make use of their entitlement. 
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Chapter 1:  Introduction 
 
Background 
The hepatitis C virus (HCV) was discovered in 1988 and, in the UK, antibody testing 
became available in 1991.  HCV infection causes a silent and progressive disease of 
the liver.  While a minority of those who become infected with HCV will clear the 
virus naturally without intervention or treatment, an estimated 60-85% of infected 
people will continue to carry the virus and are at risk of developing cirrhosis.  A 
systematic review of the worldwide literature indicated that 4%-10% of those with 
chronic HCV will develop cirrhosis after 20 years of infection (Freeman et al, 2001); 
higher rates of progression have been reported among heavy alcohol users and those 
co-infected with HIV.  Although the efficacy of anti-viral treatment has improved 
(Manns et al, 2001), prevention of HCV transmission remains a high priority. 
Injecting drug use is the most common risk factor for HCV with transmission 
associated with injecting with infected injecting equipment.  Throughout the world, 
rates of infection exceeding 50% have been detected among populations of injecting 
drug users (IDUs) (Wodak et al, 1996).  In 1999, the prevalence of HCV among drug 
injectors undergoing a named HIV test was 44% and 62% in Scotland and Glasgow, 
respectively (Hutchinson et al, 2000). 
Needle and syringe exchange, which was introduced principally to prevent HIV 
infection, had become well established in the UK in the early 1990s.   There is 
considerable evidence that this intervention has helped to control HIV transmission 
among injectors, and injectors’ incidence of HIV has been low during the 1990s.  
However, evidence suggests that needle exchange has been less effective in 
preventing the spread of HCV.  In 1999 a community wide study in Glasgow found an 
HCV prevalence of 53% among 436 IDUs who had commenced their injecting careers 
post 1989 (i.e. after the introduction of needle exchange) (A. Taylor, personal 
communication).  Among those who had commenced injecting in the previous two 
years, HCV antibody prevalence was 23%.  A further community wide study carried 
out in Glasgow in 2001-2002 found an HCV antibody prevalence of 58% among 466 
IDUs who had begun their injecting careers in the previous five years (A. Taylor, 
personal communication).  Thus, it was clear that HCV was continuing to spread 
among injectors. 
Unless safe injecting is practised throughout an injector’s entire injecting lifespan, he 
or she will be at high risk of acquiring HCV.  However, 51% of injectors recruited in 
the Glasgow study during 2001-2002 had injected with a used needle and syringe 
(n/s) in the six months prior to interview (A. Taylor, personal communication).  In 
Scotland, 34% per cent of injectors reported to the Scottish Drug Misuse Database in 
2003/2004 had injected with a used needle and syringe (n/s) in the previous month 
(ISD, 2004).  
Not enough is known about the reasons why injectors continue to share used needles 
and syringes.  It is, however, possible that sub optimal access to clean needles and 
syringes is one reason why sharing continues to be practiced.  Community wide 
surveys in Glasgow have shown significantly lower levels of needle/syringe sharing 
by IDUs who had obtained needles and syringes from a needle exchange compared 
with those who obtained no sterile equipment from this source (Hutchinson et al 
2000). 
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A survey conducted in the UK in 1997 estimated that needle exchange schemes in 
Scotland distributed between 40 and 80 syringes per injector per annum (Hickman et 
al, 2001).  If the target is to provide one sterile needle and syringe per injecting 
episode and if it is assumed that injecting occurs on average three times per day, 
then this represents a serious shortfall in supply.  In comparison, in England and 
Wales, where the prevalence of HCV among injectors is much lower than that in 
Scotland and where there is no restriction on the number of needles and syringes 
distributed, each injector receives an average of 180-380 needles and syringes per 
annum.  
Evidence such as this led to recommendations that the number of needles and 
syringes allowed to be dispensed in Scotland should be increased (SCIEH 2001, 
HEBS 2002).  In the light of these recommendations, the Lord Advocate reviewed the 
Guidelines that govern the number of needles and syringes that may be dispensed at 
any one visit to a needle exchange (NHS HDL (2002) 90).  Previously, the Lord 
Advocate’s Guidance on the distribution of sterile needles and syringes allowed five 
sets to be offered to clients attending a needle exchange for the first time.  On 
subsequent visits, up to 15 sets could be given as long as the same number of sets 
was returned for disposal.  Exceptions to this guidance included when: i) an injector 
was collecting equipment for a partner and ii) distribution occurred in a rural area or 
around a public holiday.  On such occasions, a maximum of thirty sets could be 
issued.  The new Guidelines allow a maximum 20 sets on the first visit, a maximum 
60 sets on subsequent visits and an exceptional upper limit of 120 sets for holiday 
periods when facilities are closed or are difficult to access.  These exchanges are 
subject to the return of used equipment for safe disposal.  These new Guidelines 
came into effect in December 2002. 
The Effective Interventions Unit (EIU) provided funding through the Scottish 
Executive’s Drug Misuse Research Programme to undertake an evaluation of the 
impact of the new Guidelines.  The study forms part of the EIU’s programme of 
research in the area of hepatitis C prevention (Effective Intervention Unit, 2003). 
Aim 
The aim of the evaluation was to determine if increasing the supply of sterile needles 
and syringes to injectors reduces the frequency of needle and syringe sharing. 
Objectives 
The main objectives of the study were to ascertain if the lifting of the Lord 
Advocate’s restriction on the number of needles and syringes distributed to injectors: 
• reduces the frequency of needle/syringe sharing among injectors. 
• causes any other behavioural changes among injectors, either beneficial or 
detrimental, e.g. frequency of visits to needle exchanges. 
The evaluation also sought: 
• to determine the views of needle exchange and pharmacy workers on the 
increase in supply of needles and syringes. 
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The report is divided into four chapters.  Chapter 2 describes how the study was 
undertaken.  Chapter 3 provides the results from the study.  Chapter 4 discusses the 
results and draws conclusions.  
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Chapter 2:  Methodology 
Evaluating the impact on risk behaviours 
The original proposal aimed to recruit 500 injectors who had begun injecting in the 
previous six years and interview them about their injecting behaviours, in particular 
frequency of needle/syringe sharing and frequency of visits to needle exchange, in 
the previous six months.  All respondents would be recruited at least six months 
after the introduction of the Lord Advocate’s new Guidelines on the number of 
needles and syringes distributed to injectors.  The behaviours of these 500 IDUs 
would then be compared with those reported by a sample of 500 injectors with the 
same eligibility criterion of recent injecting, who had been interviewed in 2001-2002.  
The 2001-2002 study found that in the six months prior to interview 51% had 
injected with needles and syringes previously used by someone else.  The results 
from the 2001-2002 study would provide a baseline against which to evaluate the 
effects of the increase in the Lord Advocate’s restriction on the number of needles 
and syringes distributed to injectors.  
Recruitment of the sample began in December 2003, almost one year after the 
introduction of the new Guidelines.  It very quickly became apparent to the interview 
team that most injectors were unaware that they could now obtain an increased 
number of sterile needles and syringes per visit to needle or pharmacy exchange.  
Accordingly, it was clear that the aim of the study, to determine if the increase in 
supply reduced the frequency of sharing among injectors, could not be achieved.  In 
consultation with the EIU a new method to determine the effect of the Guidelines 
was developed.  The method was as follows: 
• an awareness raising campaign would be introduced throughout Glasgow, 
consisting of posters displayed in pharmacies, needle exchanges and drug 
treatment services providing information on the new minimum and maximum 
limits and re-emphasising the message about not sharing injecting equipment.  
Credit card size cards containing the same information would also be given to 
injectors when they attended needle exchanges, pharmacies and drug treatment 
services; 
• prior to the launch of the awareness campaign 300 injectors would be recruited 
and interviewed.  The results of this phase would form the pre awareness 
baseline data.  A further 300 would be recruited approximately six weeks after 
the introduction of the awareness campaign.  Comparison would then be made 
between behaviours pre and post campaign; 
• the eligibility criterion of having started to inject in the last six years would be 
changed to include all individuals who had injected at least once in the month 
prior to interview.  This would allow the recruitment of a sample representative of 
all current injectors and not just recent initiates to injecting as in the original 
proposed method.  Injectors within this sample who had begun injecting within 
the previous six years would still be compared to the respondents in 2001-2002 
study to determine if there had been any change in behaviours over this longer 
period; 
• the questionnaire would be altered so that respondents could be asked about 
their behaviours in the last four weeks as well as the last six months, the period 
asked about in the 2001-2002 questionnaire.  Apart from this change, the 
questions would remain the same as those in the 2001-2002 questionnaire.  
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The study proceeded on the basis of this new methodology.  The pre awareness 
recruitment phase took place between February and May 2004.  Recruiting then 
ceased and the awareness campaign was put into operation.  This ran for 
approximately six weeks and then recruitment of the post-awareness sample took 
place from mid July to October 2004.  
A multiple site recruitment strategy was used to generate as representative a sample 
as possible of IDUs in Glasgow.  Sites included 16 pharmacy exchanges, Turning 
Point needle exchange and treatment service, Easterhouse GDPS needle exchange, 
the four needle exchanges operating in hostels for the homeless, the addiction teams 
located throughout Glasgow, Red Tower drug project, the Homeless Health & Social 
Care Centre, Wayside Day Centre, the Big Issue office and various street sites 
throughout Glasgow.  
After obtaining permission from each exchange and treatment service, interviewers 
either sat inside or stood outside the premises and approached IDUs.  Interviews 
took place either in a private area of the premises or in a mobile campervan that was 
parked nearby. 
For the street sample recruitment the mobile campervan was parked in streets in all 
areas throughout Glasgow in which IDUs were known to frequent.  
Interviewers explained the study to all respondents and assured them that all 
information provided by them was anonymous and confidential.  Only the initials, 
date of birth and first part of postcode were collected from each respondent and 
these were used only to identify respondents who had inadvertently been 
interviewed more than once.  After obtaining informed consent, the interviewers 
administered a structured questionnaire.  
The questionnaire covered demographics, injecting patterns, sharing of needles and 
syringes and other injecting equipment, time spent in prison, access to needle 
exchanges, knowledge of entitlement to a greater number of needles and syringes, 
frequency of needle exchange attendance and number of needles acquired per visit.  
Each interview took between 20 and 45 minutes to complete.  
Evaluation of the views of needle exchange and pharmacy workers 
All of the pharmacies and needle exchanges from which IDU respondents were 
recruited to the study were included in the exchange workers’ evaluation.  Two 
members of staff from each establishment were interviewed either inside the 
exchange or outside in the mobile campervan during a four-week period in June/July 
2004.  
Respondents were asked a series of structured, open-ended questions about their 
views on the new Guidelines.  These included their perceptions of any impact the 
Lord Advocates’ guidance had had on their service including the frequency of 
attendance by drug users.  Interviews took between five and ten minutes to 
complete. 
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Data analysis 
The behaviours (i.e. uptake and sharing of n/s) of IDUs interviewed pre and post the 
awareness raising campaign were compared using univariate analysis (see footnote 
to table 1 for further details).  
Univariate and multivariate logistic regression analyses were used to compare the 
behaviours (i.e. uptake and sharing of n/s) of pre and post awareness IDUs 
interviewed in 2004 with IDUs interviewed in 2001-2002; these analyses were 
restricted to IDUs who had begun to inject in the six years prior to recruitment.  The 
multivariate logistic regression analysis was adjusted for age, gender, recruitment 
setting, frequency of injecting and hostel residence in the previous six months. 
Descriptive statistics were used to analyse the views of pharmacy and needle 
exchange workers on the new Guidelines. 
 14 
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Chapter 3:  Results 
Sample characteristics (Table 1) 
Questionnaires were obtained from 296 and 299 injectors recruited pre and post 
awareness campaign respectively. 
The characteristics of the participants recruited in the pre and post campaign phases 
were comparable with respect to proportion of males (86% and 83%, respectively), 
age at interview (mean 32 years in both), age at first injection (mean 21 years in 
both), length of injection career (mean 11 years in both), recruitment setting (79% 
and 86% recruited in street, respectively), type of residence in the six months prior 
to interview (hostel accommodation 37% and 36% respectively), having ever been in 
treatment for drug use (93% and 88%, respectively) or in prison since onset of 
injecting (81% and 78%, respectively).  Heroin was the most common drug injected 
(by 93%) in both samples.  
A significantly higher proportion of participants from the post campaign phase (54%) 
injected drugs twice daily or more in the previous six months compared to those 
recruited pre campaign (44%) (p=0.03).  
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Table 1 Comparison Of Key Characteristics Of Current Injectors Interviewed Before And After 
The Awareness 
 Interview Undertaken 
Characteristics 
 Pre campaign 
(N=296) 
Post campaign 
(N=299) 
P1 
Age (years) 
(1 NR) 
Mean/median 
(SD) 
31.9/31.6 
(6.0) 
32.0/31.5 
(6.0) 
NS 
 
Males 
 
n (% of N) 253 (85.5%) 249 (83.3%) 
 
NS 
Age at first injection Mean/median 
(SD) 
20.5/19.0 
(5.5) 
20.8/20.0 
(5.4) 
NS 
Time since onset of injection 
(1 NR) 
Mean/median 
(SD) 
11.0/9.3 
(7.2) 
10.7/9.0 
(7.2) 
 
NS 
 
Frequency of injecting drugs in 
previous 6 month (1 NR) 
< twice/day 
≥ twice/day 
164 (55.6%) 
131 (44.4%) 
138 (46.2%) 
161 (53.8%) 
 
0.03 
Drugs injected in previous 6 
months (three most reported 
drugs) 
Heroin 
Cocaine 
Heroin + Cocaine 
275 (92.9%) 
179 (60.5%) 
115 (38.9%) 
277 (92.6%) 
169 (56.5%) 
112 (37.5%) 
 
NS 
 
Recruitment setting Street 
Needle exchange 
Treatment 
234 (79.1%) 
53 (17.9%) 
9 (3.0%) 
256 (85.6%) 
37 (12.4%) 
6 (2.0%) 
 
NS 
 
Glasgow residence 
(17 NR) 
East 
North/North West 
South 
Central 
Outside Glasgow 
69 (24.1%) 
61 (21.3%) 
26 (9.1%) 
126 (44.1%) 
4 (1.4%) 
57 (19.5%) 
51 (17.5%) 
39 (13.3%) 
136 (46.6%) 
9 (3.1%) 
 
NS 
 
Type of residence in past six 
months 
Hostel 
Other 2 
110 (37.2%) 
186 (62.8%) 
108 (36.1%) 
191 (63.9%) 
 
NS 
 
Ever treated for drug use 
 
n (% of N) 
 
273 (92.2%) 
 
264 (88.3%) 
 
NS 
1 χ2 test, t-test or where appropriate Mann Whitney U-test, NS is not significant at the 5% level 
2 other includes own home, someone else’s home, residential drug treatment, hospital, B & B, rented 
accommodation and at work 
NR non-response; SD Standard deviation 
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Risk behaviours pre and post awareness campaign (Table 2) 
There were no significant differences in injecting risk behaviours in the four weeks 
prior to interview nor in the number of n/s obtained in an average week from the 
needle exchange or pharmacy between the pre and post awareness surveys.  Almost 
80% in both samples (78% and 79% in pre and post samples, respectively), 
reported never having injected with a n/s previously used by someone else in the 
four weeks before interview; just under half of each sample had shared a spoon 
(47% and 49%, respectively) and filter (44% and 44%, respectively) in the same 
time period. 
 
Table 2 Injecting risk behaviours prior to interview 4 weeks 
 
  Interview Undertaken P1 
 
 
Pre campaign 
(N=296) 
Post campaign 
(N=299) 
 
 
Injected with N/S previously 
used by someone else (4 
NR) 
Never 
Once/month 
2-5 times/month 
>5 times/month 
229 (77.9%) 
13 (4.4%) 
31 (10.5%) 
21 (7.1%) 
237 (79.8%) 
19 (6.4%) 
27 (9.1%) 
14 (4.7%) 
NS 
Injected with N/S previously 
used by self (6 NR) 
Once/month 
2-4 times/month 
>4 times/month 
128 (43.7%) 
139 (47.4%) 
26 (8.9%) 
148 (50.0%) 
126 (42.6%) 
22 (7.4%) 
NS 
 
Source of used N/S (5 NR) Never shared 
Either family, friend or 
sexual partner only 
Casual acquaintance 2 
228 (77.8%) 
40 (13.7%) 
 
25 (8.9%) 
237 (79.8%) 
46 (15.5%) 
 
14 (4.7%) 
NS 
 
Number of different people 
from whom obtained used 
N/S (26 NR) 
Never shared 
One person 
2 or more people 
228 (80.7%) 
37 (13.1%) 
18 (6.4%) 
137 (82.9%) 
37 (12.9%) 
12 (4.2%) 
NS 
 
Shared spoons (3 NR) Never 
Once/month 
2-5 times/month 
>5 times/month 
155 (52.7%) 
27 (9.2%) 
65 (22.1%) 
47 (16.0%) 
151 (50.7%) 
26 (8.7%) 
56 (18.8%) 
65 (21.8%) 
NS 
 
Shared filter (1 NR) Never 
Once/month 
2-5 times/month 
>5 times/month 
165 (55.7%) 
25 (8.4%) 
45 (15.1% 
61 (20.5%) 
168 (56.4%) 
22 (7.4%) 
42 (14.1%) 
66 (22.1%) 
NS 
 
Passed on previously used 
N/S (4 NR) 
Never 
≤5 times 
6-20 times 
> 20 times 
221 (75.4%) 
50 (17.1%) 
12 (4.1%) 
10 (3.4%) 
231 (77.5%) 
50 (16.8%) 
10 (3.4%) 
7 (2.3%) 
NS 
1 χ2 test, t-test or where appropriate Mann Whitney U-test, NS is not significant at the 5% level 
2 Casual acquaintance includes drug dealer, someone in a shooting gallery, a fellow prisoner or a stranger 
NR Non response 
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Source and uptake of sterile needles and syringes (Table 3) 
The majority of participants in both surveys obtained their sterile needles and 
syringes from a reliable source (including needle exchange, pharmacy, drug agency, 
hospital or GP).  The number of IDUs obtaining needles and syringes from only a 
non-reliable source reduced significantly between the pre and post surveys (17% to 
9%, respectively; p<0.001). 
The frequency of visiting a needle exchange increased significantly between the pre 
and post awareness surveys (33% and 45% visited a needle exchange at least twice 
weekly, respectively; p=0.018).  
 
Table 3 Uptake of needles and syringes in the four weeks prior to interview 
 
  Interview Undertaken P1 
 
 
Pre campaign 
(N=296) 
Post campaign 
(N=299) 
 
 
Source of needles and 
syringes (11 NR)  
RS2 only 
RS and elsewhere 
elsewhere 
226 (77.4%) 
18 (6.1%) 
50 (16.9%) 
228 (76.3%) 
36 (12.0%) 
26 (8.7%) 
 
<0.001 
 
Frequency of using 
needle exchange in an 
average week3 (14 NR) 
< twice/week 
2-3 times/week 
> 3 times/week 
163 (67.4%) 
62 (25.6%) 
17 (7.0%) 
145 (55.1%) 
95 (36.1%) 
23 (8.7%) 
 
0.018 
 
Number of N/S 
obtained from needle 
exchange and /or 
pharmacist in average 
week 4 (1 NR) 
 
None 
1-5 
6-15 
16-30 
>30 
38 (12.9%) 
36 (1.2%) 
63 (21.4%) 
72 (29.2%) 
86 (29.2%) 
31 (10.4%) 
28 (9.4%) 
61 (10.4%) 
74 (24.7%) 
105 (35.1%) 
 
NS 
 
1 χ2 test, t-test or where appropriate Mann Whitney U-test, NS is not significant at the 5% level 
2 RS refers to reliable source, which includes needle exchange scheme, pharmacist, drug agency, hospital 
and GP; elsewhere includes friends, other drug users, bought on streets, sexual partner, family, theft from 
legitimate source and drug dealer 
3 Excludes 76 participants who obtained N/S from non legitimate source 
4 N/S obtained by self and/or someone else for own use 
NR Non-response 
 
IDUs’ awareness of change in Guidelines, views on ideal numbers of 
needles/syringes per visit to needle exchange and actual numbers 
obtained (Table 4) 
The maximum number of needles and syringes that IDUs believed could be obtained 
per visit from a pharmacy or needle exchange increased significantly between the 
pre and post awareness surveys (mean 26 and 37, median 20 and 25, respectively; 
p<0.001).  Few injectors, however, knew that the limit had been changed in the pre 
and post surveys (20% in both samples).  
In both the pre and post awareness surveys, the majority of IDUs stated that they 
would like to obtain up to a maximum of 30 n/s per visit to an exchange.  The actual 
number of n/s they obtained on average were 19 and 21, (median 15 and 15), pre 
and post awareness campaign, respectively.  
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Table 4 IDUs’ perceptions of maximum numbers of needles/syringes available and actual 
uptake  
 
  Interview Undertaken P1 
 
 
Pre campaign 
(N=296) 
Post campaign 
(N=299) 
 
 
Reported Max number of N/S 
available from needles 
exchange per visit (166 NR) 
 
 
mean/median 
(SD) 
 
25.7/20 
(18.5) 
 
37.2/25.0 
(30.0) 
 
<0.001 
Awareness of change in 
maximum number of N/S 
available (232 NR) 
 
n (% of N) 58 (19.6%) 61 (20.4%) NS 
Number of sterile N/S would 
like to get per visit to 
pharmacy or NE 
 
1-5 
6-15 
16-30 
>30 
34(13.0%) 
78(29.8%) 
84(32.1%) 
66(25.2%) 
39(13.9%) 
83(29.5%) 
82(29.2%) 
77(27.4%) 
NS 
Number of sterile N/S on 
average obtained by self per 
visit to pharmacy of NE2 
(22NR) 
1-5 
6-15 
16-30 
>30 
32 (13.3%) 
103 (42.9%) 
73 (30.4%) 
32 (13.3%) 
43 (16.7%) 
108 (42.0%) 
69 (26.4%) 
37 (14.4%) 
 
NS 
 
1 test, t-test or where appropriate Mann Whitney U-test, NS is not significant at the 5% level 
2 Excludes 76 participants who obtained N/S from non legitimate source 
NR Non responsive; SD Standard deviation 
 
Reasons for wanting/not wanting more needles/syringes (Tables 5 
and 6) 
Sixty-three per cent (186/296) and 58% (173/299) from the pre and post awareness 
surveys, respectively, stated that they would not wish to obtain a greater number of 
needles than they were currently receiving (data not shown).  In both samples, the 
main reason for not wishing to obtain a greater number was that what they were 
receiving already was enough for their injecting needs (206/359, 57%) (Table 5); 
however half of these respondents (181/359, 50%) stated that, on average, they 
injected with the same needle more than once (data not shown).  
 
Among those IDUs who did wish to receive more needles and syringes than they 
were currently receiving (236/595, 40%) the most common reason was to cut down 
on the number of visits to the needle exchange (74/236, 31%) (Table 6). 
 
 
 
 
Table 5 Reasons given by IDUs for not wanting any more needles than they were currently 
receiving. (N=359) 
Current number enough for injecting needs 206 57.4% 
No reasons/don’t know 46 12.8% 
Don’t like to carry them about 24 6.7% 
Don’t want them lying around 22 6.1% 
I want to stop using 18 5.0% 
The more I have the more I would use 19 5.3% 
Other 14 3.9% 
No response 10 2.8% 
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Table 6 Reasons given by IDUs for wanting to receive more needles than they were currently 
receiving (N= 236) 
So I can go to the needle exchange less often 74 31.4% 
So I could use a fresh needle every time I inject 56 23.7% 
So I don’t run of N/S 32 13.6% 
No Reason 34 14.4% 
So I wouldn’t have to share N/S 13 5.5% 
So I could give N/S to others 9 3.8% 
In case I run into problems when injecting 
(Blunt needle, missed hit) 
4 1.7% 
Other/Don’t know/ no response 14 5.9% 
 
 
Comparison of behaviours in IDUS injecting for less than six years in 
2001-2002 and 2004 (Tables 7 and 8) 
In the 2001-2002 and 2004 surveys, 385 and 170 IDUs, respectively, had begun 
injecting in the six years prior to interview and had injected at least once in the four 
weeks prior to interview. 
Comparison of key characteristics between participants in the 2001-2002 and 2004 
surveys showed that the two groups were statistically significantly different with 
respect to age, gender, frequency of drugs injected, recruitment setting and area of 
residence.  Those interviewed in 2004 were significantly more likely to be older, 
male, recruited from a street site and to reside in the centre of Glasgow, and 
significantly less likely to inject drugs more than twice daily than those interviewed 
during 2001-2002 (Table 7). 
While heroin was the most common drug injected in both the 2001-2002 and 2004 
surveys (98% and 89%, respectively), the proportion injecting cocaine (on its own) 
increased significantly from 38% in 2001-2002 to 54% in 2004 (p=0.001). 
Univariate and multivariate logistic regression analyses were used to compare 
behaviours between the 2001-2002 and 2004 samples (Table 8).  In univariate 
analysis, those interviewed in 2004 were significantly less likely than those 
interviewed in 2001-2002: 
• to use a needle exchange at least twice a week (OR 0.5, 95% CI 0.4-0.8),  
• to obtain more than sixteen n/s from an exchange in an average week (OR 
0.6, 95% CI 0.4-0.9) and  
• to have injected with a n/s previously used by someone else in the six months 
prior to interview (OR 0.3, 95% CI 0.2-0.5) than those interviewed in 2001-
2002.  
In the multivariate analysis, those interviewed in 2004 were significantly less likely 
than those interviewed in 2001-2002: 
• to obtain more than sixteen n/s from an exchange in an average week in the 
six months prior to interview (adjusted OR 0.4, 95% CI 0.2-0.6) and  
• to have injected with a n/s previously used by someone else in the six months 
prior to interview (adjusted OR 0.3, 95% CI 0.2-0.5).  
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Another multivariate analysis (not shown) also found a significant reduction in the 
proportion who reported injecting with a used n/s in the four weeks prior to interview 
among those interviewed in 2004 compared to 2001-2002 (adjusted OR 0.3; 95% CI 
0.2-0.6). 
 
Table 7 Characteristics of current injectors, with an injecting career of less than six years, recruited 
in Glasgow 2001/2002 and 2004 
Interviewed 
Sample Characteristics 
 
 
2001/02 
(N=385) 
2004 
(N=170) 
P1 
Age (years) 
(1 NR) 
 
Mean/median 
(SD) 
27.27/26.82 
(5.34) 
28.29/27.98 
(5.37) 
0.033 
Males n (% of N) 278 (72.2%) 140 (82.4%) 0.014 
Age at first injection 
 
Mean/median 
(SD) 
 
23.87/23.00 
(5.37) 
 
24.85/24 
(5.50) 
0.046 
 
Time since onset of injection (1 NR) 
 
 
Mean/median 
(SD) 
 
2.99/3.23 
(1.64) 
 
3.07/3.3 
(1.80) 
NS 
Frequency of injecting drugs in 
previous 6 month (3 NR) 
 
<2 times daily 
2-3 times daily 
> 3 times daily 
132 (34.3%) 
150 (39.0%) 
100 (26.0%) 
93 (54.7%) 
47 (27.6%) 
30 (17.6%) 
<0.001 
 
Drugs injected in previous 6 months 
(three most reported) 
 
Heroin 
Cocaine 
Heroin + Cocaine 
377 (97.9%) 
148 (38.4%) 
132 (34.3%) 
152 (89.4%) 
91 (53.5%) 
54 (31.8%) 
0.028 
Recruitment setting 
Street 
Needle exchange 
Treatment 
119 (30.9%) 
204 (54.0%) 
62 (16.1%) 
136 (80.0%) 
32 (18.8%) 
2 (1.2%) 
<0.001 
Glasgow residence 
(17 NR) 
East 
North/North 
West 
South 
Central 
Outside Glasgow 
132 (34.2%) 
65 (16.9%) 
93 (24.2%) 
42 (10.9%) 
29 (7.5%) 
36 (21.2%) 
26 (15.3%) 
20 (11.8%) 
78 (45.9%) 
7 (4.1%) 
<0.001 
Type of residence in past six months Hostel 
Other 2 
122 (31.7%) 
263 (68.3% 
44 (25.9%) 
126 (74.1%) 
NS 
Ever treated for drug use n (% of N) 312 (81.0%) 139 (81.8% NS 
1 χ2 test, t-test or where appropriate Mann Whitney U-test, NS is not significant at the 5% level  
2 other includes own home, someone else’s home, residential drug treatment, hospital, B & B, rented 
accommodation and at work 
NR non-response; SD Standard deviation 
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Views of needle exchange staff (Table 9) 
Forty exchange staff were interviewed about their views on the new Guidelines.  This 
included 33 pharmacy exchange staff from 16 pharmacies and 7 needle exchange 
staff from Turning Point exchange, Easterhouse GDPS needle exchange and the 
Homeless Health and Social Care Centre.  From the pharmacy needle exchanges, 19 
pharmacy assistants and 14 pharmacists were interviewed.  Two nurses and five 
team members were interviewed from the remaining services.  
Half of the exchanges had been operating for more than three years.  The mean 
number of staff working in exchanges was five, ranging from two to 24 (data not 
shown).  
Three members of staff had received no training in needle exchange.  Just under half 
(19/40) had been given informal training, which included being shown what to do by 
the pharmacist and other staff, on the job training, reading information and 
discussions with the pharmacy needle exchange co-ordinator.  The remainder of 
respondents (17/40) had had formal training in the form of lectures and courses. 
Most staff (37/40) knew about the new Guidelines but only 25 could correctly cite the 
maximum number of n/s that could be given out per visit.  
When asked what the exchange had done to implement the new Guidelines, almost 
all staff (39/40) said that staff had been informed and 36 said that clients had been 
informed.  
Staff reported that the most frequent way in which IDUs had been informed of the 
changes was by word of mouth and distributing information cards (cited by 14/40).  
This was closely followed by the pharmacy displaying all information that they had 
received about the change (cited by 12/40).   
The way in which IDUs were informed of the change differed between exchanges. 
Some staff commented that they would inform clients only if asked directly about the 
numbers that could be distributed. 
“Clients are told of the change if they ask.  Most just want five to 20…never had any 
wanting upper limit.” (Pharmacist) 
“If clients asked, we would inform them.” (Pharmacy assistant) 
Other exchanges were more pro-active. 
“We encourage clients to take more.” (Pharmacy assistant) 
Just under two-thirds of respondents (25/40) reported that the exchange had 
changed their policies or the way in which the exchange was run after the 
introduction of the new Guidelines.  The changes in policy included verbal and 
written policies on the number of needles and syringes to be given out per visit, how 
many n/s to be given when none were returned and how many n/s to give to new 
users.  
As the change in the Lord Advocate’s guidance is only a recommendation, 
respondents were asked how they individually, or as an exchange, decided on how 
many needles and syringes were given out to IDUs.  Respondents reported that the 
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decision was based on a number of factors.  Twenty-four staff stated that it was 
dependent mainly on the number of returns the individual brought back. 
“If they don’t have returns then we give them five.” (Pharmacy assistant). 
“If equipment is not returned then only two sets will be provided.” (Pharmacy 
assistant). 
“If people were not bringing back returns we would give out less.  We try to make 
people responsible.” (Drug worker) 
Half of the respondents (20/40) said that the number of n/s distributed per visit was 
dependent on what the service user requested and 17 said that they used their own 
experience and the exchange’s policies to guide them.  Respondents also reported 
that all these factors could change dependent on how well or otherwise they knew 
the individual IDU who was requesting needles and syringes (data not shown). 
There were mixed views on the impact that the Guidelines had had on exchanges.  A 
third (12/40) felt that the change in guidance had no impact on the 
pharmacy/exchange.  Nine staff believed that the frequency of visits by individuals 
had reduced and three respondents claimed that visits had increased.  Six staff felt 
there had been a decrease in the number of clients who visited the exchange. 
When asked their opinion on any impact on returns of used needles and syringes, 24 
had not noticed any change.  
Over a third of staff (15/40) were totally in favour of the new Guidelines.  
“I think it is a good idea, a definite improvement, keeps them safe to have fresh 
needles.  If they were a heavy user the old guidance meant that they had to reuse 
needles.” (Nurse) 
“It’s better that they are getting more so that they are not reusing them.” (Pharmacy 
assistant) 
“I think it is positive; we need to get more needles out there.  Just need to be sure 
that they are being safely disposed of.” (Drug worker) 
 
“Good idea so that they are not sharing as much.” (Pharmacist) 
A third of staff (14/40) did not personally approve of the new Guidelines and nine 
had mixed views about the change. 
“Ridiculous, it’s way too much, it’s just encouraging them.  Needles would be lying all 
over the place.  They’re not safety conscious.” (Pharmacy assistant) 
“I don’t agree with the change, the numbers are too big.  The fact that they can ask 
for 20 without returns is awful……….The old guidelines were better, even then maybe 
too many.” (Pharmacist) 
“Think it’s a bad thing, encourages them to take more drugs.  To have them lying 
around could be dangerous.” (Pharmacy assistant) 
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“In some ways it is a bad thing as it encourages them but at the same time it 
reduces risks of catching viruses so it has its good and bad points.” (Pharmacy 
assistant) 
“Good in some ways, stops sharing, but why should we give out so much for free?” 
(Pharmacy assistant)   
 
Table 9. Views of pharmacy and needle exchange staff on new Guidelines (n=40) 
  n 
Amount of time operating as an exchange Under 1 year 6 
 1-2 years 9 
 3-7 years 12 
 >7 years 8 
 DK 5 
   
Training received (1 Non-response) Informal training 19 
 Formal training 17 
 No training 3 
   
   
Aware of  Lord Advocate’s new Guidelines Yes, can state new guidance 25 
 Yes, but not sure of details 12 
 No 3 
   
What exchange has done to implement changes Informed staff 39 
 Informed clients 36 
 Changed policies 25 
   
How exchange informs service users of change Word of mouth and cards 14 
 Displays information 12 
 Word of mouth 7 
 Nothing has been done 4 
 Distributes cards 3 
   
How exchange decides how many n/s to distribute 
per visit 
Number of returns 24 
 Give client number requested 20 
 Use own experience or 
pharmacy policy 
17 
   
   
Impact of change on exchange No Impact 12 
 Decrease in frequency of visits 9 
 Increase in number of service 
users 
7 
 Decrease in number of service 
users 
6 
 Increase in frequency of visits 3 
 Other 3 
   
Impact on number of n/s returned No Change 24 
 Increase in returns 6 
 Decrease in returns 4 
 Unsure 4 
 Varied 2 
   
Personal opinion of change In favour 15 
 Not in favour 14 
 Mixed opinion 9 
 Unsure 2 
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Chapter 4:  Discussion  
The results of the study indicate that, more than a year after the introduction of the 
Lord Advocate’s new Guidelines, very few IDUs in Glasgow were aware of the 
increase in the maximum number of n/s that could be obtained per needle exchange 
visit; even a specially designed, targeted campaign failed to raise awareness.  Only 
one-fifth of injectors in both the pre and post awareness surveys knew that the limit 
had been changed.   
However, despite the failure of the awareness campaign and continuing lack of 
knowledge of the new Guidelines among many IDUs, there were some positive 
changes in behaviour between the pre and post awareness surveys.   
The maximum number of n/s that IDUs believed could be obtained per visit from a 
pharmacy or needle exchange increased significantly between the pre and post 
awareness surveys from a median of 20 n/s to a median of 25 n/s.  There was a 
decrease in the number of respondents obtaining sterile n/s from non-reliable 
sources (i.e. friends, other drug users, on street, sexual partner, family, theft from 
reliable source and drug dealer) in the post awareness phase.   
These findings could, perhaps, indicate that although the pre and post awareness 
IDUs did not appreciate that a change in policy had occurred, apropos the numbers 
of n/s being made available to them, this may be because the change happened 
gradually from the beginning of 2003.  In the pre awareness phase in early 2004, 
IDUS reported that they were receiving a median of 20 n/s, more than the 15 sets 
recommended in the old Guidelines, suggesting that the new Guidelines had already 
increased the numbers of n/s dispensed to individual IDUs.  If it is accepted that it 
may have been difficult for IDUs to perceive any obvious change between the pre 
and post awareness period (see Conclusion), the median increase, from 20 to 25, is 
impressive (i.e. a 25% increase). However, it still falls far short of the permitted 
maximum of 60 n/s per visit.   
Whilst there was no difference in n/s sharing behaviour between the pre and post 
awareness periods, the proportion indicating that they had never shared in the 
previous four weeks was nearly 80% in both phases.  Detecting any changes within 
such a short time period among a group who, during the pre awareness period, 
generally, did not share, would be very difficult.  Although non-significant, however, 
the proportion sharing more than five times per month did decline from 7.1% to 
4.7%.   
There was a significant increase in the frequency of injecting in the post awareness 
sample, however over such a short comparative period it is difficult to say whether 
this was a result in the increase in n/s or merely a coincidence. Importantly, the 
findings show that the increase in availability did not lead to an increase in sharing of 
n/s.  
About three-fifths of IDUs in both pre and post awareness surveys said that they did 
not want to obtain as many as 60 n/s per visit and they were, moreover, satisfied, 
generally, with the number they were currently receiving (a mean of 19 and 21 
(median 15 and 15), pre and post awareness campaign respectively).  In both 
samples, the main reason for not wishing to obtain a greater number was that this 
was enough for their injecting needs.  Despite this claim, half of these respondents 
stated that, on average, they injected with the same needle more than once.  It is 
clear that many IDUs do not yet know of the risks involved through re-use of their 
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own needles, nor are they perhaps aware of the danger of inadvertently re-using a 
n/s previously used by someone else if they store their used n/s along with those of 
an injecting partner (Taylor et al 2004). 
Among the two-fifths of IDUs who did wish to receive more needles and syringes 
than they were currently receiving, the most common reason was to cut down on the 
number of visits to the needle exchange.  As the role of needle exchanges and 
pharmacies extends beyond the dispensing of n/s to encompass imparting harm 
reduction messages, IDUs may fail to benefit from this if awareness and uptake of 
the increase reduces contact time with health care workers.  However, this does not 
yet appear to have happened as reported frequency of visits to a needle exchange in 
an average week also significantly increased between pre and post awareness 
phases.  
A further aim of the study was to determine changes in behaviours among recent 
initiates to injecting in 2001-2002 and in 2004.  In the 2004 survey, 170 IDUs had 
begun injecting in the previous six years and their behaviours were compared with 
those of 385 IDUs with the same length of injecting careers who had been 
interviewed in 2001-2002. 
There were some demographic differences between the two samples.  In particular 
those in the 2004 sample were more likely to be male and reside in the city centre.  
After changing the design of the study to include an awareness campaign, there was 
limited time for recruitment and the running of the campaign. Recruitment was 
targeted more towards sites where the interview team knew they could recruit larger 
numbers in a short period of time. In comparison with the 2001-2002 study, more 
respondents were recruited from street sites, including homeless hostels, most of 
which housed male IDUs, and the city centre where larger numbers of injecting drug 
users are known to frequent.  This may account for the significant difference in 
gender, recruitment setting and area of Glasgow residence from the study 
undertaken in 2001/2002.  
After controlling for these demographic differences in the analysis, injecting of 
cocaine (on its own) had increased with just over half of recent initiates in 2004 
reporting use of cocaine in the previous six months compared with just under two-
fifths of IDUs in 2001-2002.  With the increase of cocaine use it might be expected 
that the frequency of injecting would also increase.  However there was a significant 
decrease in the frequency of injecting in the previous six months in the 2004 sample 
compared with the 2001-2002 sweep. 
Moreover, those interviewed in 2004 were significantly less likely to inject with a n/s 
previously used by someone else; just over half of the 2001-2002 sample had 
injected in the previous six months with a n/s previously used by someone else in 
comparison with a quarter of the 2004 cohort.  While it cannot be said with certainty 
that there is a causal link between the introduction of the new Guidelines and these 
behaviour changes (other factors may have influenced the changes between 2001-
2002 and 2004), nevertheless, it is encouraging to note that both frequency of 
injecting and frequency of sharing used n/s has reduced among new injectors 
interviewed in 2004 in comparison with their peers in 2001-2002.   
A third aim of the study was to ascertain the views of needle exchange and 
pharmacy staff about the change in Guidelines.  The survey of 40 staff members 
showed that almost all knew about the change in Guidelines and almost all had 
informed clients of this change.  However, it appeared that, apart from displaying 
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information about the new Guidelines, some staff directly told IDUs of the change 
only if asked.  Other staff were more pro-active and explained the change to clients 
and encouraged them to take more n/s. 
Just over a third of staff approved of the new Guidelines, one third disapproved of 
them and the remainder had mixed views.  Furthermore, whilst just under two thirds 
said that the number of n/s that they dispensed depended on the number of returns 
they received, some respondents said that they decided what to dispense according 
to how well they knew the client. 
These findings – that some staff were less forthcoming in telling IDUs of the change 
in guidelines; that two-thirds were either opposed to or had mixed views of the 
change; and that dispensing can sometimes depend on the individuals requesting n/s 
– may help explain why there was so little awareness of the new Guidelines among 
the IDU population. 
 
Over one-fifth of staff members believed that frequency of visits by individual IDUs 
had reduced since the change.  This contrasts with the results of the IDU survey, 
which indicated that visits to needle exchanges had increased.  However the opening 
of more pharmacy exchanges since the new Guidelines had been implemented could 
have been a reason for a drop in the frequency of visits that some exchanges were 
experiencing. 
The majority of staff believed that the guidelines had had no impact on the number 
of needles returned to the exchange. 
Conclusion 
More than a year after the introduction of the Lord Advocate’s new Guidelines, very 
few IDUs in Glasgow were aware of the increase in the maximum number of n/s that 
could be obtained per needle exchange visit; even a specially designed, targeted 
campaign failed to raise awareness.   
After the introduction of the new Guidelines, needle exchanges and pharmacies 
displayed information and informed IDUs.  The results of the staff survey, however, 
indicated that some staff did not actively promote the increase to services users.  
Moreover, only one-third of staff approved of the new guidelines and some used their 
own judgement in deciding how many n/s should be given out.   
It may be that the reluctance to implement, or disapproval of, the guidelines among 
some staff was one reason for the low level of awareness among IDUs.  Needle 
exchange and pharmacy staff need, therefore, to be made more aware of the 
necessity to actively provide oral advice and information to their clients.   
The attitude of some staff, however, does not explain why the targeted awareness 
campaign also failed to inform the majority of IDUs.  Poster and cards were 
distributed to all exchange outlets and the cards were inserted in all n/s packs.  Yet 
this strategy, too, failed to increase knowledge among IDUs. 
One of the study findings indicated that IDUs did not, generally, wish to have any 
more n/s than they were currently receiving (about 20 per visit).  The message 
contained in the awareness campaign (or imparted by pharmacists) that more n/s 
were available was therefore meaningless to them.  The main reason for not wanting 
more n/s was that the current level was sufficient for their needs.  However it was 
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noted that half of these IDUs were re-using their own n/s; yet the awareness 
campaign cards alerted IDUs to the risks involved in this.  
Due to time constraints, the time period for the awareness campaign was six weeks.  
After this period, recruitment for the post awareness group began.  Cards and 
posters were distributed to agencies throughout the city and were placed inside the 
packs of n/s that are distributed through the pharmacy exchanges.  The cards placed 
within the packs, however, would not have reached some injectors until towards the 
end of the recruitment period.  It may be that if the campaign had run for a longer 
period it would have had more impact.  
There is some evidence, however, that leaflets are not successful in communicating 
messages to IDUs (Wright et al).  Some IDUs may, for example, have literacy 
problems that render written material ineffective.  There is perhaps a need to 
evaluate the readability of written harm reduction materials and to design and 
evaluate new ways of delivering harm reduction messages to IDUs. 
Nevertheless, there have been some positive changes in behaviours among IDUs in 
Glasgow since the introduction of the awareness campaign and since 2001.   
The maximum number of n/s that IDUs believed could be obtained per visit from a 
pharmacy or needle exchange increased significantly.  Respondents were also less 
likely to obtain sterile n/s from non-legitimate sources in the post awareness phase.  
Whilst frequency of injecting had increased, there was no increase in sharing 
behaviour.  A comparison between recent initiates to injecting in 2001-2002 and 
2004 found a decrease in both frequency of injecting and sharing in 2004. 
These changes cannot definitely be proved to arise directly from the increased 
availability of n/s; other factors may have influenced behaviour between 2001-2002 
and 2004. Nevertheless, the association between the introduction of the new 
Guidelines and behaviour changes suggests that the former may be having a positive 
impact on IDUs behaviours. It would seem prudent to continue with the current 
policy on n/s distribution.  However, the findings of this study also suggest that 
further work may need to be done by needle exchange staff to inform IDUs of their 
entitlement to a greater number of n/s, and to encourage them to make use of their 
entitlement.  
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